Keith R. Unger, MD
Disclosures: Nothing to disclose - 12/17/2018

GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE

 

CURRICULUM VITAE

 

Keith R. Unger, MD

Department of Radiation Medicine

Georgetown University Medical Center

3800 Reservoir Rd NW, LL Bles Building

Washington, DC 20007

202-444-3320; 202-444-9323

Kru2@georgetown.edu

 

Date: 1/18/2024

 

1. PERSONAL INFORMATION

A. Education:

Undergraduate:                          University of Virginia, Charlottesville, VA, USA, 1998-2002, B.A., Biology

Medical Education:              University of Virginia, Charlottesville, VA, USA, 2002-2006, M.D.

Internship:              Washington Hospital Center / Georgetown University Hospital, Department of Internal Medicine, Washington D.C, USA, 2006- 2007

Residency:              Georgetown University Hospital, Department of Radiation Medicine, Washington D.C, USA, 2007- 2011, Anatoly Dritschilo, MD

 

B. Professional Experience:

Clinical Instructor, Georgetown University School of Medicine, Washington DC, USA, 2011-2012

Assistant Professor, Georgetown University School of Medicine, Washington DC, USA, 2012-2017

Clinical Instructor, The George Washington University School of Medicine, Washington DC, USA, 2015 - 2016

Visiting Assistant Professor, University of Maryland School of Medicine, Baltimore, MD, USA, 2016 – present

Associate Professor, Georgetown University School of Medicine, Washington DC, USA, 2017 – 2021

Professor, Georgetown University School of Medicine, Washington DC, USA, 2021- present

Interim Chief and Acting Academic Chair, Department of Radiation Oncology February, MedStar Georgetown University Hospital/Georgetown University Medical Center, Washington DC, 2023 – November 2023

Chief, Department of Radiation Oncology February, MedStar Georgetown University Hospital, Washington DC, 2023 – November 2023

Physician Executive Director, MedStar Radiation Oncology, MedStar Health, Columbia, MD, November 2023 - present

 

C. Licensure:

State: DC

License No: MD037664

Initial Date: 10/6/08

Renewal/Expiration Date:   12/31/24

 

State: MD

License No: D0072381

Initial Date: 5/25/11

Renewal/Expiration Date:   9/30/25

 

State: VA

License No: 0101244480

Initial Date: 9/29/08

Renewal/Expiration Date:   5/31/24

 

D. Certification: 

Board Certification: The American Board of Radiology

Date of Certification:  5/22/2012                   

Date of Re-certification: 3/15/2025

 

E. Languages Spoken:

English

 

2. RESEARCH AND SCHOLARLY ACTIVITIES

A. Publications:

i. Original Papers in Refereed Journals

  1. Niu Y, Rashid A, Lee JM, Carrasquilla M, Conroy DR, Collins BT, Satinsky A, Unger KR, Pang D. Comparative analysis of plan quality and delivery efficiency: ZAP-X vs. CyberKnife for brain metastases treatment. Front Oncol. 2024 Jun 12:14:1333642. doi: 10.3389/fonc.2024.1333642. eCollection 2024.

 

  1. Libbey N, Gallagher L, Cantalino J, Weinberg BA, Noel MS, He AR, Radkani P, Marshall JL, Weiner LM, Jackson PG, Fishbein TM, Winslow ER, Haddad N, Rashid A, Unger KR. Patterns of Failure Following Preoperative Chemotherapy and Stereotactic Body Radiation Therapy and Resection for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer. J Gastrointest Cancer

. 2024 Jun;55(2):852-861. doi: 10.1007/s12029-023-00996-3. Epub 2024 Feb 13.

 

  1. Weinberg BA, Wang H, Noel MS, He AR, Marshall JL, Weiner LM, Fishbein TM, Hodgins NE, Winslow ER, Jackson PG, Guerra JF, Aguila F, Unger KR. Phase 1 Study of Hypofractionated Proton Beam Radiation Therapy in Adjuvant Pancreatic Cancer (PROTON-PANC). Int J Radiat Oncol Biol Phys. 2024 Feb 1;118(2):362-367. doi: 10.1016/j.ijrobp.2023.09.015. Epub 2023 Sep 16.

 

  1. McNamara ME, Loyfer N, Kiliti AJ, Schmidt MO, Shabi-Porat S, Jain SS, Martinez Roth S, McDeed AP 4th, Shahrour N, Ballew E, Lin YT, Li HH, Deslattes Mays A, Rudra S, Riegel AT, Unger K, Kaplan T, Wellstein A. Circulating cell-free methylated DNA reveals tissue-specific, cellular damage from radiation treatment. JCI Insight . 2023 Jul 24;8(14):e156529. doi: 10.1172/jci.insight.156529. DOI: 10.1172/jci.insight.156529

 

  1. Mena E, Shih J, Chung JY, Jones J, Rabiee A, Monge C, Turkbey B, Lindenberg L, Salerno KE, Kassin M, Wood B, Hernandez J, Maass-Moreno R, Saboury B, Jakhete N, Molitoris JK, Unger KR, Choyke PL, Escorcia FE. Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma. PLoS One. 2022 Nov 11;17(11):e0277407. doi: 10.1371/journal.pone.0277407

 

  1. Forsthoefel M, Hankins R, Ballew E, Frame C, DeBlois D, Pang D, Krishnan P, Unger K, Kowalczyk K, Lynch J, Dritschilo A, Collins SP, Lischalk JW. Prostate Cancer Treatment with Pencil Beam Proton Therapy Using Rectal Spacers sans Endorectal Balloons. Int J Part Ther. 2022 Apr 6;9(1):28-41. doi: 10.14338/IJPT-21-00039. eCollection Summer 2022.

 

  1. McDermott J, Wang H, DeLia D, Sweeney M, Bayasi M, Unger K, Stein DE, Al-Refaie WB. Impact of Clinician Linkage on Unequal Access to High-Volume Hospitals for Colorectal Cancer Surgery. J Am Coll Surg 2022 Jul 1;235(1):99-110. doi: 10.1097/XCS.0000000000000210

 

  1. Hinzman CP, Jayatilake M, Bansal S, Fish BL, Li Y, Zhang Y, Bansal S, Girgis M, Iliuk A, Xu X, Fernandez JA, Griffin JH, Ballew EA, Unger K, Boerma M, Medhora M, Cheema AK. An optimized method for the isolation of urinary extracellular vesicles for molecular phenotyping: detection of biomarkers for radiation exposure. J Transl Med. 2022 May 10;20(1):199. doi: 10.1186/s12967-022-03414-7. PMID: 35538547

 

  1. Nigam A, Aminpour N, Zeymo A, Desale S, Villano AM, Unger KR, Aboulafia AJ, Al-Refaie WB. National evaluation of patterns and predictors of underuse of multimodal therapy for high-risk extremity soft tissue sarcoma. Surgery. 2022 Feb 2;S0039-6060(21)01014-X. doi: 10.1016/j.surg.2021.10.034

 

  1. Rajagopal MU, Bansal S, Kaur P, Jain SK, Altadil T, Hinzman CP, Li Y, Moulton J, Singh B, Bansal S, Chauthe SK, Singh R, Banerjee PP, Mapstone M, Fiandaca MS, Federoff HJ, Unger K, Smith JP, Cheema AK. TGFβ Drives Metabolic Perturbations during Epithelial Mesenchymal Transition in Pancreatic Cancer: TGFβ Induced EMT in PDAC. Cancers (Basel)  2021 Dec 9;13(24):6204. doi: 10.3390/cancers13246204.

 

  1. Roth S, Vietsch E, Barefoot M, Schmidt M, Park M, Ramesh A, Lindberg M, Giaccone G, Riegel A, Barac A, Unger K, Wellstein A. “Cardiomyocyte-Specific Circulating Cell-Free Methylated DNA in Esophageal Cancer Patients Treated with Chemoradiation.” Gastrointest Disord (Basel). 2021 Sep;3(3):100-112. doi: 10.3390/gidisord3030011. Epub 2021 Jul 30.

 

  1. Burke AM, Yeh C, Kim S, Bergquist P, Krishnan P, Barac A, Srichai MB, Unger K. A Prospective Study of Early Radiation Associated Cardiac Toxicity Following Neoadjuvant Chemoradiation for Distal Esophageal Cancer. Front Oncol. 2020 Aug 6;10:1169. doi: 10.3389/fonc.2020.01169

 

  1. Villano AM, Zeymo A, Nigam A, Chan KS, Shara N, Unger KR, Al-Refaie WB. Radical excision for retroperitoneal soft tissue sarcoma: A national propensity-matched outcomes analysis. Surgery. 2020 Jul 21:S0039-6060(20)30330-5. doi: 10.1016/j.surg.2020.05.031.

 

  1. Forsthoefel MK, Ballew E, Unger KR, Ahn PH, Rudra S, Pang D, Collins SP, Dritschilo A, Harter W, Paudel N, Collins BT, Lischalk JW. Early Experience of the First Single-Room Gantry Mounted Active Scanning Proton Therapy System at an Integrated Cancer Center. Front Oncol. 2020 May 29;10:861. doi: 10.3389/fonc.2020.00861

 

  1. Aghdam N, McGunigal M, Wang H, Repka MC, Mete M, Fernandez S, Dash C, Al-Refaie WB, Unger KR. Ethnicity and Insurance Status Predict Metastatic Disease Presentation in Prostate, Breast, and Non-Small Cell Lung Cancer. Cancer Med. 2020 Jun 8. doi: 10.1002/cam4.3109

 

  1. Unger K, Li Y, Yeh C, Barac A, Srichai MB, Ballew EA, Girgis M, Jayatilake M, Sridharan V, Boerma M, Cheema AK. Plasma Metabolite Biomarkers Predictive of Radiation Induced Cardiotoxicity.  Radiother Oncol . 2020 Apr 20;S0167-8140(20)30199-7. doi: 10.1016/j.radonc.2020.04.018.

 

  1. Villano AM, Zeymo A, Chan KS, Unger KR, Shara N, Al-Refaie WB. Variations in Retroperitoneal Soft Tissue Sarcoma Outcomes by Hospital Type: A National Cancer Database Analysis. JCO Oncol Pract. 2020 Apr 8:JOP1900460. doi: 10.1200/JOP.19.00460.

 

  1. Badiyan S, Kaiser A, Eastman B, Forsthoefel M, Zeng J, Unger K, Chuong M. Immunotherapy and radiation therapy for gastrointestinal malignancies: hope or hype? Transl Gastroenterol Hepatol. 2020 Apr 5;5:21. doi: 10.21037/tgh.2019.10.07.

 

  1. Barish R, Lynce F, Unger K, Barac A. Management of Cardiovascular Disease in Women With Breast Cancer. Circulation. 2019 Feb 19;139(8):1110-1120. doi: 10.1161/CIRCULATIONAHA.118.039371.

 

  1. Villano AM, Zeymo A, McDermott J, Barrak D, Unger KR, Shara NM, Chan KS, Al-Refaie WB. Regionalization of Retroperitoneal Sarcoma Surgery to High-Volume Hospitals: Missed Opportunities for Outcome Improvement. Villano AM, Zeymo A, McDermott J, Barrak D, Unger KR, Shara NM, Chan KS, Al-Refaie WB.J Oncol Pract. 2019 Mar;15(3):e247-e261. doi: 10.1200/JOP.18.00349. Epub 2018 Dec 14.

 

  1. Ertreo M, Choi H, Field D, Lischalk JW, Cohen E, Lynskey GE, Caridi T, Buckley D, Unger K, Kim AY. Comparison of Cone-Beam Tomography and Cross-Sectional Imaging for Volumetric and Dosimetric Calculations in Resin Yttrium-90 Radioembolization. Cardiovasc Intervent Radiol. 2018 Jul 13. doi: 10.1007/s00270-018-2030-0

 

  1. Unger K, Mehta KY, Kaur P, Wang Y, Menon SS, Jain SK, Moonjelly RA, Suman S, Datta K, Singh R, Fogel P, Cheema AK. Metabolomics based predictive classifier for early detection of pancreatic ductal adenocarcinoma. Oncotarget. 2018 May 1;9(33):23078-23090. doi: 10.18632/oncotarget.25212. eCollection 2018 May 1.PMID: 29796173

 

  1. Repka MC, Aghdam N, Karlin AW, Unger KR. Social determinants of stage IV anal cancer and the impact of pelvic radiotherapy in the metastatic setting. Cancer Med. 2017 Nov;6(11):2497-2506. doi: 10.1002/cam4.1203. Epub 2017 Oct 4. PMID: 28980407

 

  1. Mehta KY, Wu HJ, Menon SS, Fallah Y, Zhong X, Rizk N, Unger K, Mapstone M, Fiandaca MS, Federoff HJ, Cheema AK. Metabolomic biomarkers of pancreatic cancer: a meta-analysis study. Oncotarget. 2017 Aug 18;8(40):68899-68915. doi: 10.18632/oncotarget.20324. eCollection 2017 Sep 15. PMID: 28978166

 

  1. Sanghvi SM, Lischalk JW, Cai L, Collins S, Nair M, Collins B, Unger K. Clinical outcomes of gastrointestinal brain metastases treated with radiotherapy. Radiat Oncol. 2017 Feb 28;12(1):43. doi: 10.1186/s13014-017-0774-3. PMID: 28245881; PMCID: PMC5331623.

 

  1. Lischalk JW, Burke A, Chew J, Elledge C, Gurka M, Marshall J, Pishvaian M, Collins S, Unger K. Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer. J Gastrointest Cancer. 2017 Jan 3. doi: 10.1007/s12029-016-9909-2. [Epub ahead of print]. PMID: 28044263.

 

  1. Janowski E, Timofeeva O, Chasovskikh S, Goldberg M, Kim A, Banovac F, Pang D, Dritschilo A, Unger K. Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies. Oncol Rep. 2017 Jan;37(1):57-65. doi: 10.3892/or.2016.5284. PMID: 28004119.

 

  1. Kim AY, Unger K, Wang H, Pishvaian MJ. Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: a single center experience. BMC Cancer. 2016 Jul 18;16:492. doi: 10.1186/s12885-016-2552-2.PMID: 27430276; PMCID: PMC4950251.

 

  1. Obayomi-Davies O, Kole TP, Oppong B, Rudra S, Makariou EV, Campbell LD, Anjum HM, Collins SP, Unger K, Willey S, Tousimis E, Collins BT. Stereotactic Accelerated Partial Breast Irradiation for Early-Stage Breast Cancer: Rationale, Feasibility, and Early Experience Using the CyberKnife Radiosurgery Delivery Platform. Front Oncol. 2016 May 23;6:129. doi: 10.3389/fonc.2016.00129. PMID: 27242967.

 

  1. Gabrielson A, Miller A, Banovac F, Kim A, He AR, Unger K. Outcomes and Predictors of Toxicity after Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres for Unresectable Hepatocellular Carcinoma. Front Oncol. 2015 Dec 23;5:292. doi: 10.3389/fonc.2015.00292. PMID: 26779437.

 

  1. Lischalk JW, Kole TP, Anjum HM, Obayomi-Davies O, Rashid A, Unger K. Four-dimensional computed tomography prediction of inter- and intrafractional upper gastrointestinal tumor motion during fractionated stereotactic body radiation therapy. Pract Radiat Oncol. 2016 May-Jun;6(3):176-82. doi: 10.1016/j.prro.2015.10.006. PMID: 26746816.

 

  1. Lischalk JW, Oermann E, Collins SP, Nair MN, Nayar VV, Bhasin R, Voyadzis JM, Rudra S, Unger K, Collins BT. Five-fraction stereotactic radiosurgery (SRS) for single inoperable high-risk non-small cell lung cancer (NSCLC) brain metastases. Radiat Oncol. 2015 Oct 26;10:216. doi: 10.1186/s13014-015-0525-2. PMID: 26503609.

 

  1. Gurka MK, Kim C, He AR, Charabaty A, Haddad N, Turocy J, Johnson L, Jackson P, Weiner LM, Marshall JL, Collins SP, Pishvaian MJ, Unger K.  Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma. Am J Clin Oncol. 2014 Aug 28. [Epub ahead of print]. PMID: 25171298.

 

  1. Kress MA, Sen N, Unger KR, Lominska CE, Deeken JF, Davidson BJ, Newkirk KA, Hwang J, Harter KW. Safety and efficacy of hypofractionated stereotactic body reirradiation in head and neck cancer: Long-term follow-up of a large series. Head Neck. 2015 Oct;37(10):1403-9. doi: 10.1002/hed.23763. PMID: 24824359.

 

  1. Rana N, Ju AW, Bazylewicz M, Kallakury B, He AR, Unger KR, Lee JS. Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib. Front Oncol. 2013 Dec 30;3:323. doi: 10.3389/fonc.2013.00323. PMID: 24416722.

 

  1. Jahanshahi P, Nasr N, Unger K, Batouli A, Gagnon GJ. Malignant melanoma and radiotherapy: past myths, excellent local control in 146 studied lesions at Georgetown University, and improving future management. Front Oncol. 2012 Nov 15;2:167. doi: 10.3389/fonc.2012.00167. PMID: 23162795.

 

  1. Kress MA, Ramakrishna N, Makgoeng SB, Unger KR, Potosky AL. Physician self-reported treatment of brain metastases according to patients' clinical and demographic factors and physician practice setting. Radiat Oncol. 2012 Nov 8;7:188. doi: 10.1186/1748-717X-7-188. PMID: 23136987.

 

  1. Kress MA, Collins BT, Collins SP, Dritschilo A, Gagnon G, Unger K. Scoring system predictive of survival for patients undergoing stereotactic body radiation therapy for liver tumors. Radiat Oncol. 2012 Sep 5;7:148. doi: 10.1186/1748-717X-7-148. PMID: 22950606.

 

  1. Unger K, Lominska C, Harter K. “In reply to Drs. Rwiegema and Heron,” Int J Radiat Oncol Biol  Phys, 82(4): 1323-4, 2012.

 

  1. Kress MS, Collins BT, Collins SP, Dritschilo A, Gagnon G, Unger K. Stereotactic body radiation therapy for liver metastases from colorectal cancer: analysis of safety, feasibility, and early outcomes.Front Oncol. 2012 Feb 2;2:8. doi: 10.3389/fonc.2012.00008. PMID: 22649775.

 

  1. Gill B, Oermann E, Ju A, Suy S, Yu X, Rabin J, Kalhorn C, Nair MN, Voyadzis JM, Unger K, Collins SP, Harter KW, Collins BT. Fiducial-free CyberKnife stereotactic body radiation therapy (SBRT) for single vertebral body metastases: acceptable local control and normal tissue tolerance with 5 fraction approach. Front Oncol. 2012 Apr 26;2:39. doi: 10.3389/fonc.2012.00039. PMID: 22645718.

 

  1. Lominska CE, Unger K, Nasr NM, Haddad N, Gagnon G. Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas. Radiat Oncol. 2012 May 18;7:74. doi: 10.1186/1748-717X-7-74. PMID: 22607687.

 

  1. Unger KR, Lominska CE, Chanyasulkit J, Randolph-Jackson P, White RL, Aulisi E, Jacobson J, Jean W, Gagnon GJ. Risk factors for posttreatment edema in patients treated with stereotactic radiosurgery for meningiomas. Neurosurgery. 2012 Mar;70(3):639-45. doi: 10.1227/NEU.0b013e3182351ae7. PMID: 21904263.

 

  1. Unger K, Ju A, Oermann E, Suy S, Yu X, Vahdat S, Subramaniam D, Harter KW, Collins SP, Dritschilo A, Anderson E, Collins BT. CyberKnife for hilar lung tumors: report of clinical response and toxicity. J Hematol Oncol. 2010 Oct 22;3:39. doi: 10.1186/1756-8722-3-39.PMID: 20969774.

 

  1. Unger KR, Romney DA, Koc M, Moskaluk CA, Friel CM, Foley EF, Rich TA. Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression. Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1377-82. doi: 10.1016/j.ijrobp.2010.04.016. PMID: 20656421.

 

  1. Unger KR, Lominska CE, Deeken JF, Davidson BJ, Newkirk KA, Gagnon GJ, Hwang J, Slack RS, Noone AM, Harter KW. Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1411-9. doi: 10.1016/j.ijrobp.2009.06.070.PMID: 20056341.

 

ii. Reviews or Editorials in Refereed Journals

  1. Quadri HS, Smaglo BG, Morales SJ, Phillips AC, Martin AD, Chalhoub WM, Haddad NG, Unger KR, Levy AD, Al-Refaie WB. Gastric Adenocarcinoma: A Multimodal Approach. Front Surg. 2017 Aug 3;4:42. doi: 10.3389/fsurg.2017.00042. eCollection 2017. Review. PMID: 28824918

 

  1. Lischalk JW, Repka MC, Unger K. Radiation therapy for hepatobiliary malignancies. J Gastrointest Oncol. 2017 Apr;8(2):279-292. doi: 10.21037

 

  1. Salem ME, Hartley M, Unger K, Marshall JL. Neoadjuvant Combined-Modality Therapy for Locally Advanced Rectal Cancer and Its Future Direction. Oncology (Williston Park). 2016 Jun;30(6):546-62. Review. PMID: 27306709

 

iii. Books or Chapters in Books (indicate if refereed)

  1. Malotek J, Unger K, Gutfeld O, Lee N. “Nasopharynx Cancer.” Textbook of Complex General Surgical Oncology. Morita, et al (Eds) McGraw Hill Education. 2018.

 

  1. Unger K, Jung M, Dritschilo A. “DNA, Cell Cycle,” Encyclopedia of Cancer Therapeutic Targets. Marshall J (Ed.) SpringerReference. 2017.

 

  1. Kohutek, Z, Unger K, Riaz N, Lee, N. “Oral Cavity Cancer,” Target Volume Delineation for Conformal and Intensity-Modulated Radiation Therapy. Lee N, Riaz N, Lu J (Eds.) Springer. 2015.

 

  1. Unger K, Riaz N, Chen A, Lee N. “Oral Cavity Cancers,” Target Volume Delineation and Field Lee N, Lu J (Eds.). Heidelberg. 2013

 

  1. Unger K, Lee, N. “Nasopharynx.” And “Oral Cavity” Clinical Radiation Oncology: Indications, Techniques, and Result. 3rd Edition. 2014.

 

  1. Unger K, Gurka M, Harter KW. “Radiation Therapy For Bone and Soft Tissue Sarcomas.” Sarcoma: A Multidisciplinary Approach to Treatment. Henshaw R(Ed). Springer. 2016. In press.

 

  1. Melotek J, Unger K, Gutfeld O, Lee N. “Nasopharynx Cancer,” Textbook of Complex General Surgical Oncology. Morita S, Balch C et al (Eds). The McGraw-Hill Companies, Inc. 2018

 

vi. Other Publications

  1. Unger K, Cantalino J. Radiation Therapy in Gastrointestinal Cancers: Is There a Role for Proton Therapy? ASCO Daily News. https://dailynews.ascopubs.org/do/radiation-therapy-gastrointestinal-cancers-there-role-proton-therapy. 2023

 

v. Abstracts for Conference papers and posters

  1. Unger K, Romney D, Moskaluk C, Rich T. “Thymidylate synthase and thymidine phosphorylase expression after preoperative chemoradiation in rectal cancer,” American Society of Clinical Oncology GI symposium, 7/2006

 

  1. Unger K, Gagnon G, Harter K, Jean W, Alyeshmerni D, McRae D. “Cyberknife radiosurgery for tumors of the orbit,” Oral Presentation, Cyberknife Users Meeting, 2/2008.

 

  1. Lominska C, Unger K,  Jean W, Chanyasulkit J, Collins B, Collins S, Gagnon G. “Multisession Stereotactic radiosurgery for meningioma results in low rates of post-treatment edema.” American Society for Therapeutic Radiology and Oncology, Annual Meeting, 11/2009.

 

  1. Unger K, Lominska C, Deeken J, Newkirk K, Davidson B, Liao J, Harter K. “Reirradiation using hypofractionated stereotactic radiosurgery for squamous cell carcinoma of the head and neck.” 2nd annual International Conference of Innovative Approaches in Head and Neck Oncology, 2/2009.

 

  1. Unger K, Lominska C, Deeken J, Newkirk K, Davidson B, Harter K. “Reirradiation of head and neck cancer: Dose predicts response to radiosurgery,” Cyberknife User’s Meeting, 2/2009.

 

  1. Gagnon G, Unger K, Collins B, Collins S, Henderson F, Jean W. “Evaluation of a predictive model for brain necrosis using CyberKnife radiosurgery based on the intergral logistic formulation,” CyberKnife User’s Meeting, 2/2009.

 

  1. Unger K, Walls T, Grindrod S, Jung M, Dritschilo A, Brown M. “Drug development of a novel radiosensitizing histone deacetylase inhibitor with fluorescent properties,” Radiation Research Society Annual Meeting. 9/2010.

 

  1. Unger K, Ju A, Oermann E, Suy S, Yu X, Vahdat S, Subramaniam D, Harter K, Collins S, Dritschilo A, Anderson E, Collins B. “CyberKnife for hilar lung tumors: report of clinical response and toxicity.”  American College of Physicians, CHEST, Annual Meeting. 11/2010.

 

  1. Unger K, Howard M, Slack R, Hartmann D, Newkirk K, Davidson B, Berkowitz F, Steadman K,  Lockard D, Deeken J, Harter K. “Improved outcomes in HPV-positive head and neck squamous cell carcinoma treated with concurrent cetuximab and radiation therapy.” American Society for Therapeutic Radiology and Oncology, Annual Meeting. 11/2010.

 

  1. Kress M, Collins B, Collins S, Dritschilo A, Gagnon G, Unger K. “Stereotactic body radiation therapy for liver tumors: factors predictive of outcomes and a novel scoring system.” American Society for Therapeutic Radiology and Oncology, Annual Meeting. 11/2011.

 

  1. Gurka M, Tse G, Unger K, Haddad N, Marshall J, Johnson C, Ley L, Slack R, Pishvaian M, Collins S. “Quality of life and acute radiation toxicity following hypofractionated stereotactic body radiation therapy with concurrent full-dose gemcitabine for unresectable pancreatic adenocarcinoma.” American Society of Clinical Oncology GI symposium, 1/2012.

 

  1. Rehan N, Bazylewicz M, Ju A, Unger K, Lee J, Bazylewicz, “Yttrium-90 Radioembolization is Safe in Patients with Hepatocellular Carcinoma Who Have Received Sorafenib.” Clinical Interventional Oncology. 2013

 

  1. Unger K, Prabhjit Kaur, Junrui Di, George Luta and Amrita K Cheema. Metabolomics for the Identification of Prognostic Biomarkers of  Pancreatic Cancer. AACR Annual Meeting. 2013

 

  1. Gurka M, Kim C, Haddad N, Carroll J, Charabaty A, Jackson P, Harter K, Hwang J, Weiner L, Marshall J, Collins S, Unger K. “Stereotactic Body Radiation Therapy (SBRT) Combined with Chemotherapy for Locally Advanced Pancreatic Adenocarcinoma.” ASCO GI Annual Meeting. 1/2014.

 

  1. Unger K, Collins B, Marshall J, Pishvaian M, He R, Collins S. “Outcomes after Radiation Therapy for Brain Metastases from Gastrointestinal Primaries.” ASCO GI Annual Meeting. 1/2014.

 

  1. Lischalk J, Kole T, Rashid A, Unger K. “Correlation of Fiducial Motion in 4D-CT Planning Scans with Real-Time Fiducial Tracking During Fractionated SBRT of Upper Gastrointestinal Malignancies.” ASTRO Annual Meeting. 10/2014.

 

  1. Lischalk J, Elledge C, Garcia-Bacha C, Yan K, Campbell L, Rashid A, Wu B, Pang D, Gurka M, Collins S, Unger K. “Patient-specific model predictive of gastrointestinal toxicity following stereotactic body radiation therapy (SBRT) for pancreatic cancer: preliminary finding study.” ASTRO Annual Meeting. 2015.

 

  1. Gabrielson A, Miller A, Banovac F, Kim A, He AE, Unger K. “Outcomes and Predictors of Toxicity after Selective Internal Radiation Therapy using Yttrium-90 Resin Microspheres for Unresectable Hepatocellular Carcinoma.” ASTRO Annual Meeting. 2015.

 

  1. Lischalk J, Elledge C, Gurka M, He A, Collins S, Pishvaian M, Unger K. “Five-fraction stereotactic body radiotherapy (SBRT) for local management of metastatic pancreatic cancer.” American Radium Society Annual Meeting. 2016.

 

  1. C. Yeh, B. Srichai, A. Barac, K.R. Unger. “A Prospective Study Assessing Early Cardiotoxicity after Trimodality Therapy for Esophageal Cancer.” ASTRO Annual Meeting. Volume 102, Issue 3, Supplement, Page S292018. 2018

 

B. Research Funding:

i. Current Active

Agency: MEVION Medical Systems

Identifying Number: n/a

Title of Project: Proton therapy outcomes registry

Dates of Project Period:              6/1/2021 - present

Corresponding PI: Keith Unger, MD

Total Direct Costs over all years of award: up to case rate per patient enrolled            

Total Indirect Costs over all years of award:   $                  

Total Direct plus Indirect Costs over all years of award: case rate per patient enrolled

Role on Project: Co- PI

Description: Lead research team to develop and publish novel proton therapy techniques

Percent Effort: 50%

 

ii. Submitted (Not yet funded)

Agency:     ACS                          

Identifying Number:

Title of Project: Assessing the Relative Effectiveness of Medicare Advantage Plans in Promoting Guideline Concordant Prostate Cancer Care

Dates of Project Period:    7/1/23          

Corresponding PI: Jean Mitchell

Total Direct Costs over all years of award:   $ 1,000,000

Total Indirect Costs over all years of award:   $ 200,000

Total Direct plus Indirect Costs over all years of award:  $1,200,000

Description: As co-investigator on this award I am involved in data analysis and providing clinical context

Percent Effort: 2%

Percentile (if known): Pending Review

 

Agency:     National Institute of Allergy and Infectious Diseases

Identifying Number: R44 - SBIR Grants - Phase II

Title of Project: CardioWatch: an omics-based prediction assay for cardiac late effects of acute radiation exposure

Dates of Project Period:    7/1/23 – 6/30/25          

Corresponding PI: Cheema

Total Direct Costs over all years of award:   $ 247984.00

Total Indirect Costs over all years of award:   $

Total Direct plus Indirect Costs over all years of award:  $ 386855.00

Description: As co-investigator on this award I will lead sample collection efforts, participate in data analysis, and provide clinical context

Percent Effort: 5%

Percentile (if known):

 

Agency:     NCI

Identifying Number: R43 - SBIR Grants - Phase I

Title of Project: EZ-TMF: optimized kit for circulating tumor - macrophage fusion cell isolation and enrichment

Dates of Project Period:    7/1/23 – 6/30/25          

Corresponding PI: Cheema

Total Direct Costs over all years of award:   $ 55983.00

Total Indirect Costs over all years of award:   $

Total Direct plus Indirect Costs over all years of award:  $ 87333.00

Description: As co-investigator on this award I will lead sample collection efforts, participate in data analysis, and provide clinical context

Percent Effort: 5%

Percentile (if known):

 

 

iii. Previous

Agency: MEVION Medical Systems

Identifying Number: n/a

Title of Project: Development of Advanced Proton Therapy Techniques

Dates of Project Period:              6/1/2020 – 6/1/2021

Corresponding PI: Keith Unger, MD

Total Direct Costs over all years of award:  $75,000           

Total Indirect Costs over all years of award:   $                 

Total Direct plus Indirect Costs over all years of award:  $75,000

Role on Project: Co- PI

Description: Lead research team to develop and publish novel proton therapy techniques

Percent Effort: 50%

 

Agency: NIH/NCI Subcontract Via GMG ArcData

Identifying Number: SBIR PHS2020-NCI#406 Solicitation

Title of Project: A Protype to Facilitate Patient Navigation in Support of Pancreatic Cancer Care

Dates of Project Period:              9/1/2020 – 6/15/2021

Corresponding PI: Keith Unger, MD

Total Direct Costs over all years of award:  $70,248           

Total Indirect Costs over all years of award:   $      39,536       

Total Direct plus Indirect Costs over all years of award:  $109,784           

Role on Project: PI

Description: I designed the trial and I am responsible for the overall conduct of the trial.

Percent Effort: 5.63%

 

Agency: Ruesch Center for the Cure for Gastrointestinal Cancers                           

Identifying Number: n/a

Title of Project: Adjuvant Proton Therapy for Pancreatic Cancer

Dates of Project Period:              7/1/2018 – 7/1/2021

Corresponding PI: Keith Unger, MD

Total Direct Costs over all years of award:  $25,000           

Total Indirect Costs over all years of award:   $                 

Total Direct plus Indirect Costs over all years of award:  $25,000

Role on Project: Co- PI

Description: I designed the trial and I am responsible for the overall conduct of the trial.

Percent Effort: 50%

 

Agency: Lombardi Comprehensive Cancer Center

Title: Discovery of Novel Metobolomic Plasma Biomarkers Predictive of Early Radiation Induced Cardiac Toxicity

Dates: 7/1/2018 – 7/2019

Corresponding PI: Keith Unger, MD

Total Direct Costs over all years of award:  $30,000            

Total Indirect Costs over all years of award:   $                  

Total Direct plus Indirect Costs over all years of award:  $30,000

Role on Project: PI

Percent Effort: 10%

 

Agency: Ruesch Center for the Cure for Gastrointestinal Cancers                           

Identifying Number: n/a

Title of Project: Identification of Novel Metobolomic and MRI Based Biomarkers Predictive of Early Radiation Induced Cardiac Toxicity Following Treatment for Esophageal Cancer

Dates of Project Period:              7/1/2016 – 7/1/2017

Corresponding PI: Keith Unger, MD

Total Direct Costs over all years of award:  $25,000            

Total Indirect Costs over all years of award:   $                  

Total Direct plus Indirect Costs over all years of award:  $25,000

Role on Project: PI

Description: I designed the trial and I am responsible for the overall conduct of the trial.

Percent Effort: 75%

 

Agency: American Cancer Society                            

Identifying Number: N/a

Title of Project: Metabolomics for the Identification of Prognostic Biomarkers of  Pancreatic Cancer

Dates of Project Period:              7/1/2012 – 7/1/2013

Corresponding PI: Keith Unger, MD and Amrita Cheema PhD

Total Direct Costs over all years of award:  $ 25,000           

Total Direct Costs over all years of award:   $ 25,000

Role on Project: PI

Description: I supervised the clinical aspects of the data management and analysis. 

Percent Effort:50%

 

C. Invited Lectures:

Presentation, CyberKnife User’s Meeting, San Francisco, CA, 3/2012.

 

Lecture, 13th Annual Medstar Radiation Oncology Symposium, “Advances in Radiation Therapy for Pancreatic Cancer.” Baltimore, MD. 5/2012.

 

Lecture, Ruesch Center Symposium, “Role of Radiation Therapy for the Treatment of Hepatocellular Carcinoma,” Washington, DC. 10/2013.

 

Lecture, 11th Annual Georgetown Meeting on Gastrointestinal Endoscopy, Foregut & Pancreatobiliary Surgery. “Radiation Therapy for Gastric Cancer,” Washington, DC. 3/2015

.

Lecture, Ruesch Center Symposium. “Cases in GI Cancer.” Washington, DC. 10/2015.

 

Presentation/Debate, American College of Radiology Annual Meeting. “Pros and cons of Proton Beam Radiation Therapy.” Washington DC. 11/2016.

 

Lecture, Gastric and Soft Tissue Neoplams 2017. “Radiation Therapy for Gastric Cancer” and “Radiation Therapy Advances for Retroperitoneal Sarcoma.” Washington, DC. 9/2017.

 

Lecture, Innovations in GI Cancer. “Protons: The Future of Radiation Therapy for GI Cancers.” Washington, DC. 12/2017.

 

Moderator, “Non-Colorectal Abstracts Presentations.” ASCO Annual Meeting. Chicago, IL. 6/2018.

 

Lecture. “Preoperative Therapy for Pancreatic Cancer.” The 13th Annual Georgetown Meeting on Gastrointestinal Endoscopy & Pancreatobiliary Surgery. 10/20/2018

 

Lecture. “Proton Therapy for GI Cancers.” The 9th annual Ruesch Center Symposium. 12/2018.

 

Presenter, “Can Proton Therapy be Worse? A case based presentation.” ASTRO Annual Meeting. San Antonio, TX. 10/2018.

 

Lecture. “Radiation Therapy for Soft Tissue Sarcomas.” Gastric and Soft Tissue Neoplasm Conference. Washington DC. 9/2019.

 

Lecture. “Advanced Radiation Therapy Techniques for Pancreatic Cancer.” The 43th Annual Georgetown Meeting on Gastrointestinal Endoscopy & Pancreatobiliary Surgery. Washington , DC. 10/2019

 

Presenter and panelist. “Multidisciplinary management of primary and secondary liver cancers.” Society of Interventional Radiology Course. 6/2020.

 

Lecture. “Radiation Therapy Advances for Gastric Cancer.” Gastric and Soft Tissue Neoplasm Conference. Washington DC. 9/2020

 

Lecture. “MedStar Georgetown Initial Experience with the MEVION HYPERSCAN.” MEVION Nucleus Meeting. Virtual 9/2020.

 

Presenter. “Radiation Therapy for HCC.” Medscape Oncology Decision Point. Video. 10/2020

 

Presenter. “Radiation Therapy for Esophagogastric Cancers.” Medscape Oncology Decision Point. Video 12/2020

 

Site co-leader/ Examiner. “Mock Oral examination for GI Cancers.” University of Maryland Board Examination Course. Virtual. 3/2021

 

Lecture. “MedStar Georgetown Ramp for the MEVION HYPERSCAN.” The National Association for Proton Therapy. Virtual Annual Meeting. 4/2021

 

Panelist/Lecture. “A Case-based discussion on the Unknowns of Proton Therapy.” American College of Radiology Annual Meeting. Virtual. 5/2021. 

 

Panelist/lecture. “Stereotactic body radiation therapy for liver tumors.” Society for Interventional Radiology Annual Meeting. 6/2021.

 

Site co-leader/ Examiner. “Mock Oral examination for GI Cancers.” University of Maryland Board Examination Course. Virtual. 6/2021

 

Panelist/ lecture. “Radiation therapy for Esophagogastric Cancers,” Radiation therapy for Soft tissue sarcomas.” Gastric and Soft Tissue Neoplasm Conference. Washington DC. 9/2021

 

Lecture. “Hypofractionation experience with proton therapy.” Spanish Society of Radiation Oncology Virtual Congress. 9/2021

Site co-leader/ Examiner. “Mock Oral examination for GI Cancers.” University of Maryland Board Examination Course. Virtual. 4/2022

 

 

 

E. Editorships, Editorial Boards, and Reviewing Activities

International Journal of Radiation Oncology, Biology, Physics, Ad hoc Reviewer, 2012 – present

Frontiers in Radiation Oncology, Associate Editor and Ad Hoc Reviewer, 2019 – present

Radiation Oncology, Ad Hoc Reviewer, 2015 - present

Scientific and Grant Reviewer, Dutch Cancer Society, 9/2021

 

 

 

3. TEACHING, MENTORING, AND ADVISING

A. Teaching Activities

i. Medical School Courses

 

ii. Medical School Clerkships

Name of Clerkship: RDMD390

Role: Faculty

Number of Direct Contact Hours*:125/year

Year(s) Taught: 2015 - present

Number of Students/Fellows: 20

Overall Evaluation Score: Median 5

 

Name of Clerkship: RDMD500

Role: Faculty

Number of Direct Contact Hours*:125/year

Year(s) Taught:2015 - present

Number of Students/Fellows:19

Overall Evaluation Score: Median 5

 

Average number of Residents you train per year =6

Average number of Medical students you train per year =20

 

iii. Graduate Biomedical Education Courses

Name and Course Number: Cancer Epigenetics/TBIO523

Role: Lecturer

Number of Direct* Contact Hours: 4 hrs/year

Year(s) Taught: 2015 - present

Number of Students: 30 / course

Overall Evaluation Score: median 4

 

iv. Teaching Recognition/Awards:

ARRO Educator of the Year, 2013-2014

ARRO Educator of the Year, 2019-2020

 

4. SERVICE

A. University Service:

i. Department

Director of Clinical Translational Research, 2019 – present

Lead, MGUH Dept. of Radiation Oncology, Faculty search committee (6 positions),  2019 – present

Acting Academic Chair of the Department of Radiation Oncology, MedStar Georgetown University Hospital and Georgetown School of Medicine, 1/2023 – present

 

ii. School

Interviewer, GUMC Admissions, 2015 - 2023

Member, Committee on Admission, 2016 – 2018

Preceptor, GUMC 1st year Ambulatory medicine, 2021 - 2023

 

iii. University

Member/Lombardi Representative, GUMC Research Committee, 2012 – 2015

Member, GUMC, Metabolomics Shared Resource Advisory Committee, 2020 – 2023

Member, GUMC, GUMC Shared Resources Advisory Committee, 2020 – present

Member, LCCC Clinical Research Advisory Committee, 2022-2023

Member, LCCC Executive Committee, 2023- present

 

B. MedStar or Hospital Service

Director Gastrointestinal Service, 2011 – present

MedStar Physician Leadership Development Program. 2017 -2018.

Resident Research Committee Member, MedStar Health, 2018 - present

Cancer Committee Member, MedStar Georgetown University Hospital, 2018 - present

Member, Data Safety Monitoring Committee/ Lombardi, 2011 – 2018

Member, Graduate Medical Education Committee, 2014 - present

Member, Pancreatic cancer, Liver cancer, and Upper GI service line committees, 2015 – present

Chair, Cancer Committee MedStar Georgetown University Hospital, 2018 – 2023

Urology Chief Search Committee Member, MedStar, 2019-2020

Director Gastrointestinal Service, 2011 – present

Associate Residency Program Director, 2014-2015

Residency Program Director, 2015 – present

Residency Clinical Competency Committee, 2016 – present

Member, Medical Executive Committee, MedStar Georgetown University Hospital, 2020 – present

MGUH Clinical Director of Radiation Oncology, 2021- 2023

 

C. Professional Service:

Executive Committee Member and Co-Chair, The Ruesch Center for the Cure of

Gastrointestinal Cancers, 2015 – present

Scientific Program Committee Member, American Society of Clinical Oncology. 2018 – 2019

Scientific Program Committee Chair, American Society of Clinical Oncology, 2019 – 2020

National Association of Proton Therapy Physician Advisory Committee, 2022 - present

 

5. HONORS AND AWARDS

College of Arts and Science Research Award, Universityof Virginia, 2001

Golden Key National Honor Society, University of Virginia, 2002

Bachelor of Arts with Distinction, University of Virginia, 2002

Phi Beta Kappa, University of Virginia, 2002

Association of Pathology Honor Society Award, University of Virginia School of Medicine, 2004

Radiation Research Society Scholars in Training Travel Award, 2011

Best of ASTRO Abstract Selection, 2018

Washingtonian Magazine, Best Docs, 2018 - present


6. PROFESSIONAL SOCIETY MEMBERSHIP

American Society for Therapeutic Radiology and Oncology, 2011 - present

Radiological Society of North America, 2007 - 2012

American College of Radiology, 2007- 2012

Radiation Research Society, 2009 - 2010

 

I certify that this curriculum vitae is a current and accurate statement of my professional record.

 

Signature:___________________________            Date: _________________________